1. Home
  2. SPRO vs SHMD Comparison

SPRO vs SHMD Comparison

Compare SPRO & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • SHMD
  • Stock Information
  • Founded
  • SPRO 2013
  • SHMD 1864
  • Country
  • SPRO United States
  • SHMD Germany
  • Employees
  • SPRO N/A
  • SHMD N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • SHMD
  • Sector
  • SPRO Health Care
  • SHMD
  • Exchange
  • SPRO Nasdaq
  • SHMD Nasdaq
  • Market Cap
  • SPRO 121.0M
  • SHMD 102.1M
  • IPO Year
  • SPRO 2017
  • SHMD N/A
  • Fundamental
  • Price
  • SPRO $1.90
  • SHMD $2.10
  • Analyst Decision
  • SPRO Buy
  • SHMD
  • Analyst Count
  • SPRO 4
  • SHMD 0
  • Target Price
  • SPRO $5.00
  • SHMD N/A
  • AVG Volume (30 Days)
  • SPRO 391.2K
  • SHMD 28.0K
  • Earning Date
  • SPRO 08-12-2025
  • SHMD 01-01-0001
  • Dividend Yield
  • SPRO N/A
  • SHMD N/A
  • EPS Growth
  • SPRO N/A
  • SHMD N/A
  • EPS
  • SPRO N/A
  • SHMD N/A
  • Revenue
  • SPRO $48,576,000.00
  • SHMD $85,165,542.00
  • Revenue This Year
  • SPRO N/A
  • SHMD N/A
  • Revenue Next Year
  • SPRO N/A
  • SHMD N/A
  • P/E Ratio
  • SPRO N/A
  • SHMD N/A
  • Revenue Growth
  • SPRO N/A
  • SHMD N/A
  • 52 Week Low
  • SPRO $0.51
  • SHMD $1.86
  • 52 Week High
  • SPRO $3.22
  • SHMD $4.40
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 39.50
  • SHMD 28.89
  • Support Level
  • SPRO $1.91
  • SHMD $2.11
  • Resistance Level
  • SPRO $2.18
  • SHMD $2.48
  • Average True Range (ATR)
  • SPRO 0.10
  • SHMD 0.22
  • MACD
  • SPRO 0.01
  • SHMD -0.04
  • Stochastic Oscillator
  • SPRO 19.18
  • SHMD 9.33

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: